Contract

NHS National Framework Agreement for Omalizumab

  • NHS England

UK7: Contract details notice - Procurement Act 2023 - view information about notice types

Notice identifier: 2025/S 000-086501

Procurement identifier (OCID): ocds-h6vhtk-058e04 (view related notices)

Published 30 December 2025, 4:29pm



Scope

Reference

C382504

Description

Project title: NHS National Framework for Omalizumab commencing 1st February 2026

Offer reference number: CM/TNS/25/5734

Period of framework: 1 February 2026 to 31 August 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Commercial tool

Establishes a framework


Framework

Maximum percentage fee charged to suppliers

0%

Framework operation description

Please refer to the ITO Documents for the Operation Description

Award method when using the framework

With competition

Contracting authorities that may use the framework

Establishing party only


Contract 2. Lot 1 - CM/TNS/25/5734

Suppliers (3)

Contract value

  • £87,433,000 excluding VAT
  • £104,919,600 including VAT

Above the relevant threshold

Date signed

12 December 2025

Contract dates

  • 1 February 2026 to 31 August 2027
  • Possible extension to 31 August 2029
  • 3 years, 7 months

Description of possible extension:

Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

Main procurement category

Goods

CPV classifications

  • 33600000 - Pharmaceutical products

Contract locations

  • UKC - North East (England)
  • UKD - North West (England)
  • UKF - East Midlands (England)
  • UKG - West Midlands (England)
  • UKH - East of England
  • UKJ - South East (England)
  • UKK - South West (England)

Signed contract documents

CONTRACT COPY Documents UK7 Contract Details Notice - CM-TNS-25-5734 Omalizumab.pdf

CONTRACT COPY Documents UK7 Contract Details Notice - CM-TNS-25-5734 Omalizumab


Other information

Applicable trade agreements

  • Government Procurement Agreement (GPA)

Conflicts assessment prepared/revised

Yes


Procedure

Procedure type

Open procedure


Suppliers

Celltrion Healthcare United Kingdom Limited

  • Companies House: 11685363

The Charter Building

Uxbridge

UB8 1JG

United Kingdom

Region: UKI74 - Harrow and Hillingdon

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/TNS/25/5734

MERCURY PHARMACEUTICALS LIMITED

  • Companies House: 02619880

Dashwood House

London

EC2M 1QS

United Kingdom

Region: UKI31 - Camden and City of London

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/TNS/25/5734

NOVARTIS PHARMACEUTICALS UK LIMITED

  • Companies House: 00119006

2nd Floor, The Westworks Building White City Place

London

W12 7FQ

United Kingdom

Region: UKI33 - Kensington & Chelsea and Hammersmith & Fulham

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/TNS/25/5734


Contracting authority

NHS England

  • Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

United Kingdom

Region: UKI45 - Lambeth

Organisation type: Public authority - central government